P&G Health to Consider Another Dividend: Set Feb 21 As Record Date

The pharmaceuticals and chemicals company Procter & Gamble Health Ltd (formerly Procter & Gamble Ltd) has scheduled its Board Meeting on February 12, 2025, to consider the declaration of interim dividend for the Financial Year 2024-25. The likely dividend follows the previous dividend payment of ₹260, which comprises final, interim and special dividends of ₹60, ₹50 and ₹150, respectively.

The company further informed in the exchange filing that it has set February 21, 2025, as the record date for the dividend, if declared and approved by the Board.

P&G Health Dividend History

P&G Health Management Take on Q3FY25 Performance

Mr Milind Thatte, Managing Director, P&G Health India, commented on the performance, stating, “Our results this quarter reflect the typical seasonality of shipments during this period. In addition, we’ve made choices to strengthen the execution of our integrated strategy with the deployment of a transformed go-to-market model. We’re confident these changes will deliver superior reach, distribution, and retail execution and improve our long-term competitiveness. Our strategy remains anchored on a focused product portfolio where performance is a key driver of brand preference, superiority (across product performance, packaging, brand communication, retail execution and value), constructive disruption and an agile, accountable organization. This integrated strategy continues to guide our efforts to generate sustainable, balanced top-and bottom-line growth and value creation.”

He further added, “We continue to navigate the evolving market dynamics with resilience and explore innovative solutions to ensure our trusted, quality brands remain the preferred choice for healthcare professionals and consumers alike”.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in securities market are subject to market risks, read all the related documents carefully before investing.